Floatz logo

Fludarabine

Effects of Immunotherapy

Shanghai Juncell TherapeuticsSmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Effects of Immunotherapy cohort.

Asset / SponsorPhaseRating
TIL
Shanghai Juncell Therapeutics
Phase 1/2CCC
Recombinant Wt1 Antigen-Specific Cancer Immunotherapeutic
Jules Bordet Institute
Phase 1/2CCC
Alpha-Interferon
Leiden University
Phase 1/2CCC
Nivolumab
Leiden University
Phase 1/2CCC
Ipilimumab
Radiotherapie
Phase 1CC

View all 10 →

Same molecule, other indications

Fludarabine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →
Fanconi anemiaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Adult Diffuse Large Cell LymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →